Who are Mitomycin and doxifluridine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mitomycin-and-doxifluridine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Mitomycin and doxifluridine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mitomycin and doxifluridine (Mitomycin and doxifluridine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (alkylating agent + fluoropyrimidine antimetabolite). Area: Oncology.

phase 3 Chemotherapy combination (alkylating agent + fluoropyrimidine antimetabolite) DNA (mitomycin); thymidylate synthase and nucleotide metabolism (doxifluridine) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Mitomycin and doxifluridine (Mitomycin and doxifluridine) — Asan Medical Center. Mitomycin and doxifluridine work synergistically as a chemotherapy combination, with mitomycin acting as an alkylating agent and doxifluridine as a fluoropyrimidine antimetabolite to inhibit DNA synthesis and induce cancer cell death.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Mitomycin and doxifluridine TARGET	Mitomycin and doxifluridine	Asan Medical Center	phase 3	Chemotherapy combination (alkylating agent + fluoropyrimidine antimetabolite)	DNA (mitomycin); thymidylate synthase and nucleotide metabolism (doxifluridine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (alkylating agent + fluoropyrimidine antimetabolite) class)

Asan Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mitomycin and doxifluridine — Competitive Intelligence Brief. https://druglandscape.com/ci/mitomycin-and-doxifluridine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab